24/7 Market News Snapshot 21 August, 2025 – Evoke Pharma, Inc. (NASDAQ:EVOK)
DENVER, Colo., 21 August, 2025 (www.247marketnews.com) – (NASDAQ:EVOK) are discussed in this article.
Evoke Pharma, Inc. (NASDAQ:EVOK) is experiencing a notable surge in its stock price, with shares trading at $7.27, reflecting a remarkable increase of 24.70% from the previous close of $5.83. This bullish momentum is underscored by a trading volume of 1.51 million, suggesting strong investor enthusiasm and confidence in the company’s future. Analysts are recommending close observation of EVOK, as its upward trajectory may attract additional investment interest within the biotechnology sector.
In a pivotal advance for the company, Evoke Pharma announced the listing of its U.S. Patent No. 12,377,064 in the FDA’s Orange Book, which pertains to GIMOTI® (metoclopramide) nasal spray, specifically for patients suffering from moderate to severe symptoms of gastroparesis. Matt D’Onofrio, Chief Executive Officer of Evoke Pharma, emphasized the significance of the patent in safeguarding the company’s investment in innovation and enhancing treatment alternatives for healthcare providers and patients alike. The patent, effective until November 17, 2038, extends the protection of GIMOTI beyond an earlier expiration date of May 15, 2030.
GIMOTI is a groundbreaking FDA-approved nasal spray formulated to alleviate symptoms associated with diabetic gastroparesis in adults, marking it as a first-of-its-kind treatment in its category. This non-oral delivery mechanism offers a vital alternative for patients when traditional oral medications prove inadequate due to the complications associated with the condition, which significantly impairs the stomach’s ability to empty.
As the only FDA-approved treatment specifically targeting gastroparesis, GIMOTI signifies a substantial advancement for the millions affected by this condition. Evoke Pharma remains committed to addressing the unmet needs of this patient population through continued innovation and advocacy in the biopharmaceutical space.